Online citations, reference lists, and bibliographies.
← Back to Search

Novel Strategies In The Oral Delivery Of Antidiabetic Peptide Drugs – Insulin, GLP 1 And Its Analogs

R. Ismail, I. Csóka
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
&NA; As diabetes is a complex disorder being a major cause of mortality and morbidity in epidemic rates, continuous research has been done on new drug types and administration routes. Up to now, a large number of therapeutic peptides have been produced to treat diabetes including insulin, glucagon‐like peptide‐1 (GLP‐1) and its analogs. The most common route of administration of these antidiabetic peptides is parenteral. Due to several drawbacks associated with this invasive route, delivery of these antidiabetic peptides by the oral route has been a goal of pharmaceutical technology for many decades. Dosage form development should focus on overcoming the limitations facing oral peptides delivery as degradation by proteolytic enzymes and poor absorption in the gastrointestinal tract (GIT). This review focuses on currently developed strategies to improve oral bioavailability of these peptide based drugs; evaluating their advantages and limitations in addition to discussing future perspectives on oral peptides delivery. Depending on the previous reports and papers, the area of nanocarriers systems including polymeric nanoparticles, solid lipid nanoparticles, liposomes and micelles seem to be the most promising strategy that could be applied for successful oral peptides delivery; but still further potential attempts are required to be able to achieve the FDA approved oral antidiabetic peptide delivery system. Graphical abstract Figure. No caption available.
This paper references
10.1002/AIC.690410814
Transdermal delivery of peptide and protein drugs: An overview
B. Amsden (1995)
10.1208/s12248-011-9307-4
Absorption Enhancers: Applications and Advances
B. Aungst (2011)
10.1016/J.IJDM.2011.01.011
Public health and prevention of blindness in diabetes
Einar Stefánsson (2015)
10.1016/j.carbpol.2014.06.045
pH sensitive N-succinyl chitosan grafted polyacrylamide hydrogel for oral insulin delivery.
Piyasi Mukhopadhyay (2014)
10.1016/j.ijpharm.2009.07.022
Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins.
E. Khafagy (2009)
10.1515/9783111576855-015
J
Seguin Hen (1824)
SOLID LIPID NANOPARTICLES: A REVIEW
P. Ekambaram (2012)
10.1515/9783111576855-009
D
Saskia Bonjour (1824)
10.23937/2377-3634/1410006
Recent Advances in Insulin Therapy for Diabetes
A. Ahmad (2014)
10.1517/17425247.2016.1142526
Recent advances in oral delivery of peptide hormones
Pegah Varamini (2016)
10.1201/9781420039832
Therapeutic peptides and proteins : formulation, processing, and delivery systems
A. Banga (2005)
10.1016/j.biomaterials.2011.07.086
Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins.
Kiran Sonaje (2011)
10.1016/j.nano.2013.07.011
Biotinylated liposomes as potential carriers for the oral delivery of insulin.
X. Zhang (2014)
Solid lipid nanoparticles (SLN) as carrier system for the controlled release of drugs
RH Muller (2000)
MICROEMULSIONS AS CARRIER FOR NOVEL DRUG DELIVERY: A REVIEW
UdayKumar Gopal (2011)
10.1517/17425247.2014.917077
Oral peptide and protein delivery: intestinal obstacles and commercial prospects
Alice L Smart (2014)
10.1038/nrd4363
Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies
S. Mitragotri (2014)
10.4103/0250-474X.95608
Noninvasive Routes of Proteins and Peptides Drug Delivery
Jitendra (2011)
10.1016/j.biomaterials.2011.12.038
Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery.
Fang-Yi Su (2012)
10.1016/j.biomaterials.2014.05.020
Augmented cellular trafficking and endosomal escape of porous silicon nanoparticles via zwitterionic bilayer polymer surface engineering.
M. Shahbazi (2014)
10.1166/JBN.2013.1572
N-octyl-N-Arginine chitosan micelles as an oral delivery system of insulin.
Z. Zhang (2013)
10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J
Intestinal permeation enhancers.
B. Aungst (2000)
10.2147/DDDT.S116443
Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach
K. Karimi (2016)
10.1208/s12248-014-9687-3
Strategic Approaches to Optimizing Peptide ADME Properties
Li Di (2014)
10.3923/JMS.2015.209.220
Oral Delivery of Insulin for Treatment of Diabetes: Classical Challenges and Current Opportunities
M. Ansari (2015)
10.1023/A:1015992828666
Synthesis of Palmitoyl Derivatives of Insulin and Their Biological Activities
M. Hashimoto (2004)
10.1016/j.ijpharm.2013.02.040
Skin penetration enhancers.
M. Lane (2013)
10.1016/j.arcped.2012.01.013
[Et al].
P. Cochat (2012)
10.3109/1061186X.2014.934688
Polymeric micelles as drug carriers: their lights and shadows
M. Yokoyama (2014)
10.2217/nnm.10.143
Nanocarriers for pulmonary administration of peptides and therapeutic proteins.
Fernanda Andrade (2011)
10.1016/J.LFS.2004.05.027
The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer.
Z. Değim (2004)
10.3390/md13041819
Stability of Chitosan—A Challenge for Pharmaceutical and Biomedical Applications
E. Szymańska (2015)
10.1515/9783111548050-034
W
Lohmarer Stadtgeschichte (2005)
10.1016/J.JDDST.2015.06.016
A focus on mucoadhesive polymers and their application in buccal dosage forms
E. Russo (2016)
10.1016/j.jconrel.2016.04.012
Dual chitosan/albumin-coated alginate/dextran sulfate nanoparticles for enhanced oral delivery of insulin.
M. Lopes (2016)
10.1039/C2SM06811G
Multidrug resistance protein P-glycoprotein does not recognize nanoparticle C60: experiment and modeling
Xue Xu (2012)
Winnicka
E. Szymańska (2015)
10.1517/17425247.5.1.45
Nanoparticle strategies for the oral delivery of insulin
C. Damgé (2008)
X
J. Wang (2016)
10.1016/b978-0-12-384931-1.00003-9
C
J. Lackie (2013)
10.1007/s11095-008-9816-8
Synthesis, Characterization and In Vivo Efficacy of PEGylated Insulin for Oral Delivery with Complexation Hydrogels
A. Tuesca (2008)
10.1515/9783111419787-003
H
Yu-Qin Cao (1824)
10.1016/j.ijbiomac.2013.08.002
Combining two technologies: multifunctional polymers and self-nanoemulsifying drug delivery system (SNEDDS) for oral insulin administration.
D. Sakloetsakun (2013)
10.3109/03639045.2014.972412
In vitro lipolysis tests on lipid nanoparticles: comparison between lipase/co-lipase and pancreatic extract
V. Jannin (2015)
10.1016/J.TRAC.2015.06.014
PLGA-based nanoparticles: A new paradigm in biomedical applications
Shweta R. Sharma (2016)
10.1016/j.jconrel.2016.05.015
Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates.
Jianyong Sheng (2016)
10.1016/j.ejpb.2015.04.030
Effect of different intestinal conditions on the intermolecular interaction between insulin and cell-penetrating peptide penetratin and on its contribution to stimulation of permeation through intestinal epithelium.
N. Kamei (2015)
10.1016/j.jconrel.2014.09.031
Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: strategies and industrial perspectives.
V. Pawar (2014)
10.3109/10717544.2013.819611
Oral delivery of therapeutic proteins and peptides: a review on recent developments
S. Gupta (2013)
10.5040/9781474284028.0024
S
A. Kumar (1824)
10.1016/j.jconrel.2016.04.024
Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model.
N. Shrestha (2016)
10.1007/s11095-010-0130-x
Phospholipids and Lipid-Based Formulations in Oral Drug Delivery
G. Fricker (2010)
10.1111/cbdd.12055
The Future of Peptide‐based Drugs
D. Craik (2013)
10.1093/jb/mvn134
Modification of antimicrobial peptide with low molar mass poly(ethylene glycol).
G. Zhang (2008)
10.1016/j.msec.2016.06.059
A composite hydrogel system containing glucose-responsive nanocarriers for oral delivery of insulin.
L. Li (2016)
Therapeutic Peptides and Proteins
A. K. Banga (2006)
10.3390/md13052890
Alginate Hydrogels Coated with Chitosan for Wound Dressing
M. C. Straccia (2015)
10.1016/j.addr.2016.01.010
Oral delivery of macromolecular drugs: Where we are after almost 100years of attempts.
E. Moroz (2016)
10.1016/J.JCONREL.2007.10.023
Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes.
Nartaya Thirawong (2008)
10.1002/jps.22054
Delivery of therapeutic proteins.
D. Pisal (2010)
Regulatory science based drug formulation -model proposal for QBD in R&D phase, In: 11 th Central European Symposium on Pharmaceutical Technology, Belgrad
I Csoka (2016)
10.1016/j.biomaterials.2014.07.026
The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium.
F. Araújo (2014)
10.4172/2161-0444.1000227
Enhancing the Oral Bioavailability of Peptide Drugs by using ChemicalModification and Other Approaches
N. Yin (2014)
10.2174/1389557053765583
Advancements in the anti-diabetes chemotherapeutics based on amino acids, peptides, and peptidomimetics.
R. Jain (2005)
Winnicka. stability of chitosan—a challenge for pharmaceutical and biomedical applications
E Szymańska (2015)
Delivery Technologies for Biopharmaceuticals Peptides
L. Jorgensen (2009)
10.4155/TDE.12.40
Polymer-based oral peptide nanomedicines.
E. P. Herrero (2012)
Recent progress in peptides and proteins delivery by noninvasive routes
LL Wearly (1991)
10.4103/0975-7406.76478
Mucoadhesive drug delivery systems
Rahamatullah Shaikh (2011)
10.1016/j.biotechadv.2014.07.006
A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules.
Bibi F Choonara (2014)
10.1016/j.ijbiomac.2014.08.040
pH-sensitive chitosan/alginate core-shell nanoparticles for efficient and safe oral insulin delivery.
Piyasi Mukhopadhyay (2015)
Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems.
N. Ghilzai (2006)
10.3109/03639045.2014.947507
Development of β-cyclodextrin-based sustained release microparticles for oral insulin delivery
Bernadette D’souza (2015)
Proteins and Peptides: Pharmacokinetic
R. J. Mrsny (2010)
A Review on Microemulsion Based System
D. Gupta (2011)
10.1016/j.ijpharm.2014.05.047
In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin.
Fabian Hintzen (2014)
Structure
S. F. Zhou (2008)
10.1016/0168-3659(96)01353-3
Enhancement of the intestinal absorption of peptides and nonpeptides
B. Aungst (1996)
10.15272/AJBPS.V4I40.645
Diabetes mellitus ? a devastating metabolic disorder
Piero Mn (2015)
10.1016/j.colsurfb.2009.09.001
Biodegradable polymeric nanoparticles based drug delivery systems.
A. Kumari (2010)
10.1016/j.carbpol.2015.09.103
Positive/negative surface charge of chitosan based nanogels and its potential influence on oral insulin delivery.
J. Wang (2016)
10.1016/j.jconrel.2008.09.091
A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Cheng-hao Jin (2009)
10.1208/s12248-014-9670-z
Lipid-Based Drug Carriers for Prodrugs to Enhance Drug Delivery
J. Zaro (2014)
Oral delivery of Macromolecular Drugs: Barriers, Strategies And Future Trends- Low Molecular Mass Permeation Enhancers In Oral Delivery Of Macromolecular Drugs, Springer: New York.2009
AB Schnürc (2009)
10.1016/j.ijpharm.2016.07.016
Development and evaluation of viscosity-enhanced nanocarrier (VEN) for oral insulin delivery.
Mariam Boushra (2016)
10.2174/092986712799945003
Converting peptides into drug leads by lipidation.
L. Zhang (2012)
Regulatory science based drug formulation model proposal for QBD in R&D phase
I. Csoka (2016)
10.1515/9783486731620-002
I
John B. Shoven (1824)
10.1007/s11095-014-1303-9
A Novel Suspension Formulation Enhances Intestinal Absorption of Macromolecules Via Transient and Reversible Transport Mechanisms
S. Tuvia (2014)
10.1080/21688370.2016.1156805
Chemically modified peptides and proteins - critical considerations for oral delivery
S. T. Buckley (2016)
10.1111/ics.12248
Optimization and development of stable w/o/w cosmetic multiple emulsions by means of the Quality by Design approach
A. Kovács (2016)
10.1016/S0140-6736(05)61503-6
T
D. Davies (1998)
10.1007/s001250051529
Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice
J. Joseph (2000)
10.1016/j.ejps.2016.08.055
The application of P‐gp inhibiting phospholipids as novel oral bioavailability enhancers — An in vitro and in vivo comparison
Manuel Weinheimer (2017)
Development of a microparticle - based DPI formulation of ciprofloxacin hydrochloride applying the QbD approach
I Csoka (2016)
Approaches for Enhancing Oral Bioavailability of Peptides and Proteins
Wang Don (2014)
10.1186/1745-6673-2-16
Nanotechnology-based drug delivery systems
S. Suri (2007)
REVIEW ON MICROEMULSION AS FUTURISTIC DRUG DELIVERY
Faizi Mu Zaffar (2013)
Pharmaceutical composition for oral insulin administration comprising a tablet core and an anionic copolymer coating
甘霈 (2014)
10.1016/S1043-6618(03)00158-0
P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement.
M. Varma (2003)
10.1021/cr9000226
ABC efflux pump-based resistance to chemotherapy drugs.
Paul D. W. Eckford (2009)
10.1016/j.ejpb.2012.02.009
Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose.
M. Niu (2012)
10.1515/9783111548050-035
Z
Axel M. Gressner (2012)
10.2174/157016311796799062
20 Years of Lipid Nanoparticles (SLN & NLC): Present State of Development & Industrial Applications
R. Mueller (2011)
Handbook of Encapsulation and Controlled Release
S. Diekmann Stephan Drusch (2019)
10.1038/clpt.2009.159
Orally Administered Glucagon‐Like Peptide‐1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects
R. Steinert (2009)
10.1136/bmj.i1525
Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials
(2016)
Solid lipid nanoparticles as attractive drug vehicles: composition
M. G. Moritz (2016)
10.22377/AJP.V3I2.244
Recent trends in protein and peptide drug delivery systems
H. Gupta (2009)
10.1248/BPB.B13-00661
Discussion about several potential drawbacks of PEGylated therapeutic proteins.
F. Zhang (2014)
Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase.
A. Abuchowski (1977)
10.4155/TDE.11.114
Oral peptide delivery: prioritizing the leading technologies.
D. Brayden (2011)
10.1515/9783111697888-007
E
Adam S. Opalski (1824)
10.1208/s12248-012-9441-7
In Vitro and In Vivo Evaluation of a Water-in-Oil Microemulsion System for Enhanced Peptide Intestinal Delivery
Dongyun Liu (2012)
10.1016/j.tibtech.2009.07.009
Therapeutic application of peptides and proteins: parenteral forever?
Zuzana Antošová (2009)
10.1021/bc800258v
Development of poly(ethylene glycol) conjugated lactoferrin for oral administration.
Y. Nojima (2008)
10.1186/s12951-015-0136-y
Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes
G. Sharma (2015)
10.1515/9783111548050-024
M
M. Sankar (1824)
10.1016/j.addr.2016.06.005
Intestinal permeation enhancers for oral peptide delivery.
S. Maher (2016)
10.2174/0929866521666140807112148
Novel non-invasive protein and peptide drug delivery approaches.
L. Wallis (2014)
Oral Delivery of Macromolecular Drugs: Barriers
A. B. Schnürc (2009)
10.1016/S0168-8227(11)70011-0
Incretin effect: GLP-1, GIP, DPP4.
Kyriafeos Kazafeos (2011)
10.1038/nrd1695
Protein drug stability: a formulation challenge
S. Frokjaer (2005)
10.3109/9781420078077
Proteins and Peptides : Pharmacokinetic, Pharmacodynamic, and Metabolic Outcomes
R. Mrsny (2009)
10.1016/B978-0-7020-7222-2.00022-6
V
M. Millodot (2018)
Incretin effect: GLP-1
K. Kazakos (2011)
10.1016/j.addr.2012.09.037
Liposomal drug delivery systems: from concept to clinical applications.
T. Allen (2013)
10.1515/9783111438443-006
N
Città DI Torino (1824)
BUCCOADHESIVE DRUG DELIVERY SYSTEMS: A REVIEW
Ravi Bhalodia (2010)
10.1016/j.biomaterials.2010.12.044
The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo.
Ho-Ngoc Nguyen (2011)
10.1016/j.pharmthera.2015.07.003
Cell-penetrating peptides transport therapeutics into cells.
J. Ramsey (2015)
10.1515/9783111548050-035
Z
Axel M. Gressner (2012)
10.1016/S0939-6411(00)00084-9
Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?
T. Jung (2000)
10.1155/2015/753569
Cytotoxicity and biological efficacy of exendin-4-encapsulated solid lipid nanoparticles in INS-1 cells
Hee-Sook Jun (2015)
10.1007/s10439-016-1558-x
Delivery of Exenatide and Insulin Using Mucoadhesive Intestinal Devices
V. Gupta (2016)
Microemulsion formulation for biologicals, WO 2011004395 A1.2011
R. S. Mody (2011)
NOVEL APPROACHES FOR INSULIN DELIVERY : CURRENT STATUS
M. VarshneyH. (2012)
10.1152/AJPCELL.1991.260.2.C183
Functional biology of intestinal goblet cells.
R. Specian (1991)
10.1515/9783050077338-026
Y
E. M. S. J. xviii (1824)
Development of a microparticle-based DPI formulation of ciprofloxacin hydrochloride applying the QbD approach, Drug Design Devel Ther
K Karimi (2016)
10.2217/nnm.09.110
Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery.
E. Roger (2010)
10.1016/j.drudis.2012.03.002
Cell-penetrating peptides: classes, origin, and current landscape.
Francesca Milletti (2012)
10.1053/J.GASTRO.2007.03.054
Biology of incretins: GLP-1 and GIP.
L. Baggio (2007)
10.2174/092986712803251548
Peptides as therapeutics with enhanced bioactivity.
D. Goodwin (2012)
10.1016/j.jconrel.2016.02.009
A novel combined strategy for the physical PEGylation of polypeptides.
E. Ambrosio (2016)
10.1016/j.xphs.2016.02.018
Methocel-Lipid Hybrid Nanocarrier for Efficient Oral Insulin Delivery.
Mariam Boushra (2016)
10.1002/0471475734.CH10
Oral Protein and Peptide Drug Delivery
R. Soltero (2005)
10.1016/j.ejpb.2010.09.016
Preparation and evaluation of alginate-chitosan microspheres for oral delivery of insulin.
Y. Zhang (2011)
10.1038/srep18039
Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides
Y. Li (2015)
10.1021/bi101926u
How PEGylation enhances the stability and potency of insulin: a molecular dynamics simulation.
C. Yang (2011)
10.1016/j.jconrel.2008.03.018
Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme.
Mao-Bo Cheng (2008)
10.3390/ijms17020185
Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos
M. Kristensen (2016)
10.1016/j.jfda.2015.01.007
Application of polymeric nanoparticles and micelles in insulin oral delivery.
M. Alai (2015)
10.1163/156856208786440479
Engineering strategies to enhance nanoparticle-mediated oral delivery
Yvonne J. Yamanaka (2008)
10.1007/s11095-014-1513-1
The Glucose-Lowering Potential of Exenatide Delivered Orally via Goblet Cell- Targeting Nanoparticles
X. Li (2014)
Peptides and proteins in pharmaceuticals
MP Ratnaparkh (2011)
10.1016/j.addr.2012.07.012
Fatty acids as therapeutic auxiliaries for oral and parenteral formulations.
Michael J. Hackett (2013)
10.1515/9783111413426-013
L
Il Liceo (1824)
Novel carrier systems for oral delivery of insulin
PV Shinde (2013)
Thiomers: A New Generation of Mucoadhesive Polymers
M. Wagh (2009)
10.1016/B978-0-12-405191-1.00012-0
Synthesis
P. Wakeley (2013)
10.1515/9783111576855-016
K
Martin P. Catherwood (1824)
10.1002/jps.24102
In vivo evaluation of thiolated chitosan tablets for oral insulin delivery.
G. Millotti (2014)
10.1016/J.EJPB.2007.07.009
Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation.
Y. Youn (2008)
Jain A
S. Gupta (2013)
10.1515/9783111697888-004
B
B. A. R. Kernfach (1824)
10.1515/9783111576855-012
G
G.V.T.V. Weerasooriya (1824)
10.1016/J.DRUDIS.2006.08.005
Is the oral route possible for peptide and protein drug delivery?
M. Morishita (2006)
10.1016/j.jconrel.2012.01.043
PLGA-based nanoparticles: an overview of biomedical applications.
F. Danhier (2012)
Sudhakar
S. U. Krishnan (2015)
10.1016/J.IJDM.2009.08.001
Chronic complications of diabetes mellitus in newly diagnosed patients
I. Heydari (2010)
10.2147/IJN.S19917
Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation
M. Niu (2011)
10.22037/IJPR.2010.25
Peptide and Protein Delivery at a Glance
R. Aboofazeli (2010)
10.1016/j.ijpharm.2015.06.018
Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation.
E. Pallagi (2015)
10.1016/j.jconrel.2016.03.020
Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems.
Dongdong Zhang (2016)
10.22037/IJPR.2010.26
Synthesis of Baclofen; an Alternative Approach
M. H. H. Tehrani (2003)
10.1615/CRITREVTHERDRUGCARRIERSYST.V22.I5.10
Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies.
S. Galindo-Rodriguez (2005)
Cell-penetrating peptides: classes
F. Milletti (2012)
10.3109/10717544.2015.1043472
Enhanced oral bioavailability of insulin using PLGA nanoparticles co-modified with cell-penetrating peptides and Engrailed secretion peptide (Sec)
Siqi Zhu (2016)
10.4155/tde.13.104
Basics and recent advances in peptide and protein drug delivery.
Benjamin J. Bruno (2013)
Eudragit  L 100 / N - trimethylchitosan chloride microspheres for oral insulin delivery
P. A. Burke Mitragotri
10.4155/ppa.14.15
Formulation strategies to improve oral peptide delivery.
S. Maher (2014)
10.1111/dom.12596
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
S. Madsbad (2016)
10.1111/j.1463-1326.2009.01150.x
Oral insulin – a review of current status
H. Iyer (2010)
Microemulsion formulation for biologicals
RS Mody (2011)
10.1016/j.jconrel.2016.02.031
Dextran-b-poly(lactide-co-glycolide) polymersome for oral delivery of insulin: In vitro and in vivo evaluation.
Mona Alibolandi (2016)
10.1007/s40005-016-0253-0
Cell penetrating peptides as an innovative approach for drug delivery; then, present and the future
Santosh K Bashyal (2016)
10.1016/j.ejpb.2016.06.016
Freeze-dried eudragit-hyaluronan multicompartment liposomes to improve the intestinal bioavailability of curcumin.
Ana Catalan-Latorre (2016)
10.2174/138920106777950852
Novel delivery technologies for protein and peptide therapeutics.
T. Kumar (2006)
10.1016/S0168-3659(03)00328-6
Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles.
J. Panyam (2003)
10.1016/j.ijpharm.2014.07.049
Preparation and characterization of PEG-coated silica nanoparticles for oral insulin delivery.
T. Andreani (2014)
10.1517/17425247.2015.1018175
Polymeric nanoparticle drug delivery technologies for oral delivery applications
Eric M. Pridgen (2015)
10.1016/j.drudis.2009.10.009
Synthetic therapeutic peptides: science and market.
P. Vlieghe (2010)
10.1039/c6nr00294c
In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy
F. Araújo (2016)
10.1166/JBN.2015.1924
Chitosan-Modified Cationic Amino Acid Nanoparticles as a Novel Oral Delivery System for Insulin.
S. Abbad (2015)
10.1016/j.ijpharm.2016.07.003
New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach.
E. Pallagi (2016)
10.1016/j.jconrel.2015.09.012
Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach.
Liat Soudry‐Kochavi (2015)
Peptide and protein delivery at a glance. Iran
R. Aboofazeli (2003)
10.1371/journal.pone.0086064
Oral Delivery of Exenatide via Microspheres Prepared by Cross-Linking of Alginate and Hyaluronate
B. Zhang (2014)
10.1016/b978-0-12-384931-1.00016-7
P
J. Lackie (2013)
Delivery technologies for biopharmaceuticals : peptides, proteins, nucleic acids and vaccines
L. Jorgensen (2009)
10.3390/ijms17020263
Intracellular Delivery of Proteins with Cell-Penetrating Peptides for Therapeutic Uses in Human Disease
A. Dinca (2016)
10.1016/j.jconrel.2015.12.008
Efficient mucus permeation and tight junction opening by dissociable "mucus-inert" agent coated trimethyl chitosan nanoparticles for oral insulin delivery.
Mengshuai Liu (2016)
10.2147/IJN.S81715
pH-sensitive poly(lactide-co-glycolide) nanoparticle composite microcapsules for oral delivery of insulin
S. Sun (2015)
10.1002/jps.23640
Preparation and characterization of insulin-surfactant complexes for loading into lipid-based drug delivery systems.
P. Li (2013)
10.1016/j.biotechadv.2015.02.010
Polymer-based nanoparticles for oral insulin delivery: Revisited approaches.
P. Fonte (2015)
Challenges in Delivery of Therapeutic Genomics and Proteomics
A. Misra (2011)
10.2174/187221108786241679
Microemulsions: a novel approach to enhanced drug delivery.
S. Talegaonkar (2008)
NOVEL SMART pH SENSITIVE CHITOSAN GRAFTED ALGINATE HYDROGEL MICROCAPSULES FOR ORAL PROTEIN DELIVERY: II. EVALUATION OF THE SWELLING BEHAVIOR
Mohy Eldin Ms. (2015)
10.1007/3-540-26367-5_1
A
A. Spring (2005)
Lipid nanoparticles (SLN and NLC) for drug delivery
EB Souto (2007)
Novel Approaches for Oral Delivery of Insulin and Current Status of Oral Insulin Products
P KineshV. (2010)
10.2217/nnm.15.36
Oral insulin delivery using deoxycholic acid conjugated PEGylated polyhydroxybutyrate co-polymeric nanoparticles.
K. Chaturvedi (2015)
MICROEMULSION - PROPHESY OF DRUG DELIVERY SYSTEM
S. Sruthi (2014)
Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drugdelivery systems
D. Zhang (2016)
10.1016/j.phrs.2016.05.016
Oral delivery of insulin via polyethylene imine-based nanoparticles for colonic release allows glycemic control in diabetic rats.
L. Salvioni (2016)
10.1016/J.REACTFUNCTPOLYM.2010.10.002
Oral protein delivery: Current status and future prospect
K. Park (2011)
Oral insulin – a challenging approach in insulin delivery
SU Krishnan (2015)
10.1016/j.ejpb.2015.03.027
Effect of mucoadhesive polymers on the in vitro performance of insulin-loaded silica nanoparticles: Interactions with mucin and biomembrane models.
T. Andreani (2015)
10.1016/j.jsps.2014.06.004
A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives
Abdul Muheem (2016)
10.1016/J.IJPHARM.2005.04.016
A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: Investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats.
A. Cilek (2005)
10.18433/J3RC77
Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy.
T. Bansal (2009)
10.2307/j.ctvrnfqk1.10
? ? ? ? f ? ? ? ? ?
A. ADoefaa (2003)
10.1080/00498250701867889
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.
S. Zhou (2008)
10.1152/ajpgi.00107.2011
A review of the efficacy and safety of nanoparticle-based oral insulin delivery systems.
J. W. Card (2011)
10.1007/s11095-013-1067-7
The Immunogenicity of Polyethylene Glycol: Facts and Fiction
H. Schellekens (2013)
Peptide and Protein Delivery, 1st ed
C. Van der Valle (2011)
X
A. Patel (2014)
10.1016/j.biomaterials.2015.07.045
Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: A controlled dual protein-drug delivery system.
N. Shrestha (2015)
10.1016/J.JDDST.2015.06.020
Reduction of the in vivo burst release of insulin-loaded microparticles
A. S. Hasan (2015)
10.1016/J.MOLSTRUC.2010.11.049
Adsorption investigation of MA-DTPA chelating resin for Ni(II) and Cu(II) using experimental and DFT methods
X. Zhao (2011)
10.1016/j.msec.2016.05.119
Solid lipid nanoparticles as attractive drug vehicles: Composition, properties and therapeutic strategies.
M. Geszke-Moritz (2016)
10.1016/B978-0-12-384931-1.00018-0
R
J. Lackie (2013)
10.3390/molecules18066734
Eudragit® L100/N-Trimethylchitosan Chloride Microspheres for Oral Insulin Delivery
E. Marais (2013)
10.1016/j.msec.2016.08.083
Preparation of chitosan-based multifunctional nanocarriers overcoming multiple barriers for oral delivery of insulin.
L. Li (2017)
Development of b-cyclodextrinbased sustained release microparticles for oral insulin delivery
B. D’Souza (2015)
10.1208/pt060116
Eudragit S100 entrapped insulin microspheres for oral delivery
D. Jain (2008)
10.1007/BF02867128
Oral Insulin—Fact or Fiction?
K. Gowthamarajan (2003)
10.1016/j.ejps.2016.12.020
Development of nanostructured lipid carriers containing salicyclic acid for dermal use based on the Quality by Design method
A. Kovács (2017)
10.2174/0929866521666140807114240
Recent advances in protein and Peptide drug delivery: a special emphasis on polymeric nanoparticles.
Ashaben Patel (2014)
X
M. Liu (2017)
10.1016/j.ijpharm.2010.08.020
Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution.
D. Vllasaliu (2010)
Kiill, et al., Preparation and characterization of PEG-coated silica nanoparticles for oral insulin
T. Andreani (2014)
10.1016/j.addr.2003.10.025
Penetration enhancers.
A. Williams (2004)
10.1023/A:1016444808000
Chitosans as Absorption Enhancers for Poorly Absorbable Drugs. 1: Influence of Molecular Weight and Degree of Acetylation on Drug Transport Across Human Intestinal Epithelial (Caco-2) Cells
N. G. Schipper (2004)
10.1016/j.biomaterials.2011.08.087
A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery.
M. Chen (2011)
Commercial challenges and emerging trends in oral delivery of peptide and protein drugs: A review
A. Sharma (2011)
10.1016/j.ejpb.2010.07.002
Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats.
G. Sharma (2010)
10.1016/S1359-6446(03)02623-0
Peptide and protein drug delivery to and into tumors: challenges and solutions.
V. Torchilin (2003)
10.1201/b14413
Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form
M. Gibson (2001)
10.1248/BPB.29.1790
Nanocarriers: promising vehicle for bioactive drugs.
M. Rawat (2006)
L 100 / N-Trimethylchitosan Chloride Microspheres for Oral Insulin Delivery
E. Marais (2013)
Development of a microparticle-based DPI formulation of ciprofloxacin hydrochloride applying the QbD approach
K. Karimi (2016)
Thiolated Chitosan
D Sakloetsakun (2010)
10.1152/physrev.00013.2014
Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease.
D. Sandoval (2015)
Role of protease inhibitors in Insulin therapy of Diabetes : are these beneficial ?
(2015)
10.22270/JDDT.V5I4.1163
A REVIEW ON NOVEL APPROACHES FOR ORAL DELIVERY OF INSULIN
N. Pandit (2015)
10.1016/j.ijbiomac.2016.07.019
Development of amphoteric alginate/aminated chitosan coated microbeads for oral protein delivery.
A. Omer (2016)



This paper is referenced by
10.1007/s40199-019-00316-w
Review of recently used techniques and materials to improve the efficiency of orally administered proteins/peptides
Y. H. Y. Ibrahim (2019)
10.1002/jcph.1131
Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
T. Bækdal (2018)
10.1016/bs.apcsb.2017.06.002
Protein-Protein Interaction Modulators for Epigenetic Therapies.
Bárbara I Díaz-Eufracio (2018)
10.2147/IJN.S161240
Synthesis and characterization of a novel peptide-grafted Cs and evaluation of its nanoparticles for the oral delivery of insulin, in vitro, and in vivo study
Ghullam Reza Barbari (2018)
10.3390/molecules25051161
Recent Advances in Encapsulation, Protection, and Oral Delivery of Bioactive Proteins and Peptides using Colloidal Systems
S. Perry (2020)
10.3390/md18040180
Effects of Cyclization on Activity and Stability of α-Conotoxin TxIB
Xincan Li (2020)
10.1016/j.xphs.2019.01.025
Overcoming Poor Tabletability of Bulky Absorption Enhancers by Spray Drying Technology.
W. Fan (2019)
10.3390/pharmaceutics11110599
Encapsulation in Polymeric Nanoparticles Enhances the Enzymatic Stability and the Permeability of the GLP-1 Analog, Liraglutide, Across a Culture Model of Intestinal Permeability
R. Ismail (2019)
DDDT_A_217211 3405..3418
Mohsen Doostmohammadi (2019)
10.14232/SYRPTBRS.2019.OP18
Quality by Design driven development of Liraglutide loaded nanocarriersystem designed for oral delivery
R. Ismail (2019)
10.1248/bpb.b17-00798
Exploration of the Key Factors for Optimizing the in Vivo Oral Delivery of Insulin by Using a Noncovalent Strategy with Cell-Penetrating Peptides.
N. Kamei (2018)
10.1039/c7cs00536a
Molecular engineering solutions for therapeutic peptide delivery.
H. Acar (2017)
10.1016/j.ejpb.2020.04.025
Hydrophobic ion pairing of a GLP-1 analogue for incorporating into lipid nanocarriers designed for oral delivery.
R. Ismail (2020)
10.1016/j.lfs.2017.10.025
Anti‐diabetic potential of peptides: Future prospects as therapeutic agents
Marya (2018)
10.1007/s11095-019-2620-9
Synthesis and Statistical Optimization of Poly (Lactic-Co-Glycolic Acid) Nanoparticles Encapsulating GLP1 Analog Designed for Oral Delivery
R. Ismail (2019)
10.1039/c9bm00003h
Succinylated casein-coated peptide-mesoporous silica nanoparticles as an antibiotic against intestinal bacterial infection.
Gaomei Zhao (2019)
10.1080/10717544.2017.1413443
Enteric-coated insulin microparticles delivered by lipopeptides of iturin and surfactin
Xiaoying Xing (2018)
10.1016/j.peptides.2017.10.004
Peptide welding technology – A simple strategy for generating innovative ligands for G protein coupled receptors
G. Calo’ (2018)
10.1002/adbi.201800221
Effect of Glucose on Liposome–Plasma Protein Interactions: Relevance for the Physiological Response of Clinically Approved Liposomal Formulations
S. Palchetti (2019)
10.1021/acsnano.7b09109
Self-Assembling Myristoylated Human α-Defensin 5 as a Next-Generation Nanobiotics Potentiates Therapeutic Efficacy in Bacterial Infection.
Ruyi Lei (2018)
10.1016/j.jconrel.2020.07.037
Ionic liquid-mediated delivery of insulin to buccal mucosa.
Amogh Vaidya (2020)
10.1016/j.cis.2018.02.002
Encapsulation, protection, and delivery of bioactive proteins and peptides using nanoparticle and microparticle systems: A review.
D. J. Mcclements (2018)
10.1016/j.peptides.2018.01.002
Recent insights in the use of nanocarriers for the oral delivery of bioactive proteins and peptides
P. Batista (2018)
10.1039/c9me00143c
Protein biomaterials for theranostic applications
Kamia Punia (2019)
10.1080/10408398.2018.1528206
Recently isolated antidiabetic hydrolysates and peptides from multiple food sources: a review
Bababode Adesegun Kehinde (2018)
10.2174/1566524019666191010095522
A Brief Overview of the Oral Delivery of Insulin as an Alternative to the Parenteral Delivery.
A. Macedo (2020)
10.1016/J.APSUSC.2017.11.055
Hydrogen Bonded Niosomes for Encapsulation and Release of Hydrophilic and Hydrophobic Anti-Diabetic Drugs: An Efficient System for Oral Anti-Diabetic Formulation
Noufel Samed (2017)
10.3390/molecules24234209
Nanoparticle Delivery Systems in the Treatment of Diabetes Complications
E. B. Souto (2019)
10.1080/02652048.2019.1692945
Development and characterization of exendin-4 loaded self-nanoemulsifying system and in vitro evaluation on Caco-2 cell line
Y. Aktaş (2019)
10.3390/pharmaceutics12010048
In Vitro, Ex Vivo and In Vivo Evaluation of Microcontainers for Oral Delivery of Insulin
J. R. Jørgensen (2020)
10.1007/s40262-018-0728-4
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes
C. Granhall (2018)
10.1007/s42823-019-00033-z
Oral delivery of insulin via mesoporous carbon nanoparticles for colonic release allows glycemic control in diabetic rats
Haorong Lin (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar